Cannabinoid Receptor Agonist-induced Apoptosis of Human Prostate Cancer Cells LNCaP Proceeds through Sustained Activation of ERK1/2 Leading to G1 Cell Cycle Arrest*

We have recently shown that the expression levels of both cannabinoid receptors CB1 and CB2 are higher in human prostate cancer cells than in normal prostate epithelial cells, and treatment of LNCaP cells with WIN-55,212-2 (a mixed CB1/CB2 agonist) resulted in inhibition of cell growth and induction of apoptosis (Sarfaraz, S., Afaq, F., Adhami, V. M., and Mukhtar, H. (2005) Cancer Res. 65, 1635-1641). This study was conducted to understand the mechanistic basis of these effects. Treatment of LNCaP cells with WIN-55,212-2 (1-10 μm; 24 h) resulted in: (i) an arrest of the cells in the G0/G1 phase of the cell cycle; (ii) an induction of p53 and p27/KIP1; (iii) down-regulation of cyclins D1, D2, E; (iii) decrease in the expression of cdk-2, -4, and -6; (iv) decrease in protein expression of pRb; (v) down-regulation of E2F (1-4); and (vi) decrease in the protein expression of DP1 and DP2. Similar effects were also observed when androgen-independent PC3 cells were treated with WIN-55,212-2 (5-30 μm). We further observed sustained up-regulation of ERK1/2 and inhibition of PI3k/Akt pathways in WIN-55,212-2-treated cells. Inhibition of ERK1/2 abrogated WIN-55,212-2-indued cell death suggesting that sustained activation of ERK1/2 leads to cell cycle dysregulation and arrest of cells in G0/G1 phase subsequently leading to an induction of apoptosis. Further, WIN-55,212-2 treatment of cells resulted in a dose-dependent increase in Bax/Bcl-2 ratio in such a way that favors apoptosis. The induction of apoptosis proceeded through down-regulation of caspases 3, 6, 7, and 9 and cleavage of poly (ADP-ribose) polymerases. Based on these data we suggest that cannabinoid receptor agonists should be considered as novel agents for the management of prostate cancer.

[1]  A. Porter,et al.  Target to apoptosis: A hopeful weapon for prostate cancer , 1997, The Prostate.

[2]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[3]  K. Vermeulen,et al.  Cell cycle and apoptosis , 2003, Cell proliferation.

[4]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[5]  M. Vitale,et al.  Control by the endogenous cannabinoid system of ras oncogene‐dependent tumor growth , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  V. Adhami,et al.  Cannabinoid receptor as a novel target for the treatment of prostate cancer. , 2005, Cancer research.

[7]  A. Saraste,et al.  Morphologic and biochemical hallmarks of apoptosis. , 2000, Cardiovascular research.

[8]  M. Kastan,et al.  p53 and ATM: cell cycle, cell death, and cancer. , 1997, Advances in cancer research.

[9]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[10]  M. L. de Ceballos,et al.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. , 2001, Cancer research.

[11]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[12]  A. Giordano,et al.  The Rb family of cell cycle regulatory factors: clinical implications. , 2000, International journal of oncology.

[13]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[14]  I. Galve-Roperh,et al.  Control of the cell survival/death decision by cannabinoids , 2001, Journal of Molecular Medicine.

[15]  G. Núñez,et al.  Caspases: the proteases of the apoptotic pathway , 1998, Oncogene.

[16]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[17]  Christine E. Canman,et al.  P53, cell cycle control and apoptosis: Implications for cancer , 1995, Cancer and Metastasis Reviews.

[18]  R. Rouzier,et al.  Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines , 2004, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[19]  J. Falck,et al.  2-Arachidonoylglycerol , 2004, Cancer Research.

[20]  W. El-Deiry,et al.  Cell cycle control as a basis for cancer drug development (Review). , 2000, International journal of oncology.

[21]  K. Kinzler,et al.  p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. , 1995, Genes & development.

[22]  N. L. Thangue,et al.  Regulation of E2F transcription by cyclin E–Cdk2 kinase mediated through p300/CBP co-activators , 2000, Nature Cell Biology.

[23]  J. Slingerland,et al.  Deregulation of the cell cycle in cancer. , 2000, Cancer detection and prevention.

[24]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[25]  N. Pavletich.  Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.

[26]  P. Hinds,et al.  Cyclins and cdks in development and cancer: a perspective , 2005, Oncogene.

[27]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[28]  M. Kasten,et al.  pRb and the Cdks in apoptosis and the cell cycle , 1998, Cell Death and Differentiation.

[29]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[30]  M. Cortés,et al.  Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation , 2000, Nature Medicine.

[31]  T. Owa,et al.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. , 2001, Current medicinal chemistry.

[32]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[33]  J. Isaacs,et al.  Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.

[34]  W. Kaelin,et al.  Functions of the retinoblastoma protein. , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  T. Klein.  Cannabinoid-based drugs as anti-inflammatory therapeutics , 2005, Nature Reviews Immunology.

[36]  P. Malone,et al.  Prostate , 1995 .

[37]  M. Molinari.  Cell cycle checkpoints and their inactivation in human cancer , 2000, Cell proliferation.

[38]  S. Elledge,et al.  Cdk inhibitors: on the threshold of checkpoints and development. , 1994, Current opinion in cell biology.

[39]  R. Weinberg,et al.  Cell-cycle control and its watchman , 1996, Nature.

[40]  Brian David Dynlacht,et al.  New insights into cyclins, CDKs, and cell cycle control. , 2005, Seminars in cell & developmental biology.

[41]  J. Nevins,et al.  Role of the Rb/E2F pathway in cell growth control , 1997, Journal of cellular physiology.

[42]  Massimo Loda,et al.  Role of p27 in Prostate Carcinogenesis , 2004, Cancer and Metastasis Reviews.

[43]  J. Harbour,et al.  Rb function in cell-cycle regulation and apoptosis , 2000, Nature Cell Biology.

[44]  Y Taya,et al.  RB kinases and RB-binding proteins: new points of view. , 1997, Trends in biochemical sciences.

[45]  T. Bisogno,et al.  The endocannabinoid signalling system: Biochemical aspects , 2005, Pharmacology Biochemistry and Behavior.